Pharma BD Deal Intelligence
Enbrel mega-deal built Amgen into global biotech leader with 30-year franchise
Full analysis, sources & comparables →Ranks computed across 828 graded deals (Critic + Outcome Score both present).
Amgen agrees to buy Immunex in record biotech deal valued at about $16 billion in cash and stock.
The FTC cleared the $16 billion acquisition of Immunex Corporation by Amgen Inc., resolving anticompetitive concerns in the market for colony stimulating…
Amgen Inc. filed Form 8-K reporting the completion of its acquisition of Immunex Corporation.
Source summaries from our enrichment pipeline; follow links for originals.
All 6 sources with sentiment breakdown →
Amgen acquired Immunex for approximately $16 billion in stock and cash, gaining full rights to Enbrel (etanercept), the blockbuster anti-TNF therapy for rheumatoid arthritis. The deal was 85% stock (0.44 Amgen shares per Immunex share) and 15% cash ($4.50 per share).
| Deal | Year | Value | Outcome |
|---|---|---|---|
| Amgen Inc. / Immunex Corporation (this deal) | 2001 | $16.0B | 91 |
| Amgen Inc. / Immunex Corporation | 2002 | $16.0B | 92 |
| Amgen Inc. / Micromet Inc. | 2012 | $1.2B | 88 |
| Amgen Inc. / Five Prime Therapeutics | 2021 | $1.9B | 78 |
| Amgen Inc. / Horizon Therapeutics plc | 2022 | $27.8B | 72 |
| Amgen Inc. / Otezla (from Celgene/BMS) | 2019 | $13.4B | 68 |
| Amgen Inc. / BeiGene Ltd. | 2020 | $2.8B | 68 |
← Browse all deals · How we score deals
More: 2001 deals · Amgen Inc. deals · Dermatology deals